See more : Aikchol Hospital Public Company Limited (AHC.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Dalrada Financial Corporation (DFCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dalrada Financial Corporation, a leading company in the Consulting Services industry within the Industrials sector.
- Jinduicheng Molybdenum Co., Ltd. (601958.SS) Income Statement Analysis – Financial Results
- Jadestone Energy plc (JSE.L) Income Statement Analysis – Financial Results
- Rockridge Resources Ltd. (ROCK.V) Income Statement Analysis – Financial Results
- Xiabuxiabu Catering Management (China) Holdings Co., Ltd. (XIAXF) Income Statement Analysis – Financial Results
- Gold State Resources Inc. (CYNXF) Income Statement Analysis – Financial Results
Dalrada Financial Corporation (DFCO)
About Dalrada Financial Corporation
Dalrada Financial Corporation and its subsidiaries provide clean energy, healthcare, technology, and precision engineering solutions. It operates through Engineering, Health, Information Technology, Education, and Corporate. The company engages in the manufacture and distribution of medical disposables, hospital equipment and furniture, medical devices, and laboratory and dental products, as well as sanitizing, disinfectant, and PPE products and services; and provision of mechanical contract services. It also provides advanced solutions for the harvesting and recycling of energy to maximize the capture and reuse of thermal energy for integrated heating and cooling applications, such as industrial, commercial, and residential sectors. In addition, the company offers software and technology solutions that specializes in test engineering, accessibility engineering, product engineering and application modernization; cleaning solutions using electrostatic machines to spray and deodorize residential spaces, healthcare facilities, hospitality, transportation, manufacturing, automotive, schools/education systems, and other facilities. Further, it provides trained nursing and medical assistants for hospitals and home health facilities; and regenerative therapy as a potential solution for the prevention, detection, and treatment of cellular breakdown associated with aging and various other conditions, as well as explores various products and services within the immunization and personal protective equipment industry. The company has operations in Malaysia, India, the United Kingdom, and the United States. Dalrada Financial Corporation was founded in 1982 and is based in Escondido, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.74M | 19.27M | 3.41M | 1.18M | 72.16K | 0.00 | 70.38M | 19.48M | 13.53M | 4.19M | 25.25M | 3.45M | 2.55M | 17.30M | 34.40M | 30.60M | 11.60M | 14.40M | 11.10M | 10.20M | 10.30M | 7.20M | 10.50M | 9.50M | 9.30M | 4.20M | 1.80M |
| Cost of Revenue | 20.68M | 8.76M | 2.47M | 625.92K | 75.00K | 0.00 | 63.93M | 16.53M | 10.30M | 2.30M | 23.20M | 2.74M | 1.87M | 13.30M | 21.80M | 15.50M | 9.60M | 11.60M | 9.80M | 4.70M | 4.90M | 5.50M | 8.10M | 8.10M | 7.20M | 2.80M | 1.40M |
| Gross Profit | 9.06M | 10.51M | 934.72K | 552.24K | -2.84K | 0.00 | 6.45M | 2.95M | 3.22M | 1.89M | 2.05M | 710.00K | 679.00K | 4.00M | 12.60M | 15.10M | 2.00M | 2.80M | 1.30M | 5.50M | 5.40M | 1.70M | 2.40M | 1.40M | 2.10M | 1.40M | 400.00K |
| Gross Profit Ratio | 30.46% | 54.53% | 27.44% | 46.87% | -3.94% | 0.00% | 9.17% | 15.13% | 23.84% | 45.13% | 8.13% | 20.57% | 26.66% | 23.12% | 36.63% | 49.35% | 17.24% | 19.44% | 11.71% | 53.92% | 52.43% | 23.61% | 22.86% | 14.74% | 22.58% | 33.33% | 22.22% |
| Research & Development | 120.00K | 657.00K | 520.51K | 471.96K | 50.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 2.05M | 2.20M | 2.50M | 4.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 29.47M | 20.07M | 8.98M | 2.77M | 721.85K | 91.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.47M | 20.07M | 8.98M | 2.77M | 721.85K | 91.98K | 11.19M | 5.58M | 4.20M | 7.59M | 12.44M | 8.72M | 7.78M | 13.70M | 10.30M | 9.40M | 3.20M | 4.40M | 4.40M | 4.40M | 4.40M | 6.00M | 5.20M | 3.50M | 3.80M | 2.90M | 1.70M |
| Other Expenses | 433.56K | 308.53K | 114.40K | 1.23M | 2.26M | -183.97K | 0.00 | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 3.33M | 4.80M | 700.00K | 900.00K | 400.00K | 800.00K | 700.00K | 300.00K | 200.00K | 300.00K | 100.00K | 200.00K | 200.00K | 200.00K | 200.00K |
| Operating Expenses | 30.02M | 20.72M | 9.50M | 3.24M | 771.90K | 91.98K | 11.19M | 6.93M | 4.20M | 7.59M | 12.44M | 8.97M | 13.16M | 20.70M | 13.50M | 14.50M | 3.60M | 5.20M | 5.10M | 4.70M | 4.60M | 6.30M | 5.30M | 3.70M | 4.00M | 3.10M | 1.90M |
| Cost & Expenses | 50.70M | 29.48M | 11.98M | 3.87M | 846.89K | 91.98K | 75.12M | 23.46M | 14.50M | 9.89M | 35.64M | 11.71M | 15.03M | 34.00M | 35.30M | 30.00M | 13.20M | 16.80M | 14.90M | 9.40M | 9.50M | 11.80M | 13.40M | 11.80M | 11.20M | 5.90M | 3.30M |
| Interest Income | 79.76K | 4.45K | 6.28K | 8.77K | 853.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.55M | 1.30M | 670.27K | 1.04M | 853.18K | 945.24K | 2.70M | 1.71M | 1.93M | 0.00 | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 400.00K | 400.00K | 300.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 707.57K | 252.94K | 112.50K | 46.60K | 774.74K | 91.98K | 1.34M | 510.00K | 1.18M | 1.07M | 972.00K | 806.00K | 3.33M | 4.80M | 700.00K | 900.00K | -400.00K | -800.00K | -700.00K | -300.00K | -200.00K | 300.00K | 100.00K | 200.00K | 200.00K | 200.00K | 200.00K |
| EBITDA | -17.37M | -9.88M | 783.99K | -1.39M | 1.22M | -91.98K | -3.40M | -3.47M | 203.00K | -4.62M | -9.42M | -7.45M | -9.16M | -11.90M | -200.00K | 1.40M | -1.20M | -1.60M | -3.10M | 1.10M | 1.00M | -4.30M | -2.80M | -2.10M | -1.70M | -1.50M | -1.30M |
| EBITDA Ratio | -58.40% | -49.73% | -243.88% | -223.53% | -1,073.71% | 0.00% | -19.69% | -18.15% | 1.45% | -166.85% | -37.29% | -168.77% | -364.90% | -32.37% | 25.58% | 4.58% | 7.76% | -11.11% | -27.93% | 10.78% | 16.50% | -55.56% | -49.52% | -41.05% | -35.48% | -54.76% | -100.00% |
| Operating Income | -20.96M | -10.22M | -8.57M | -2.69M | -774.74K | -91.98K | -4.74M | -3.98M | -972.00K | -5.70M | -10.39M | -8.26M | -12.48M | -16.70M | -900.00K | 600.00K | -1.60M | -2.40M | -3.80M | 800.00K | 800.00K | -4.60M | -2.90M | -2.30M | -1.90M | -1.70M | -1.50M |
| Operating Income Ratio | -70.48% | -53.03% | -251.57% | -228.23% | -1,073.71% | 0.00% | -6.73% | -20.44% | -7.19% | -135.92% | -41.14% | -239.28% | -490.15% | -96.53% | -2.62% | 1.96% | -13.79% | -16.67% | -34.23% | 7.84% | 7.77% | -63.89% | -27.62% | -24.21% | -20.43% | -40.48% | -83.33% |
| Total Other Income/Expenses | 332.24K | -1.00M | 8.57M | 211.54K | 1.14M | -945.24K | 7.77M | -121.00K | -1.92M | -1.16M | -3.30M | -1.63M | -1.71M | -8.10M | -9.00M | -13.00K | -2.10M | 0.00 | 0.00 | 0.00 | -700.00K | -300.00K | 2.10M | 1.80M | 1.60M | 800.00K | 500.00K |
| Income Before Tax | -20.63M | -11.44M | 1.22K | -2.48M | 365.85K | -1.04M | 3.03M | -4.28M | -2.90M | -6.86M | -13.69M | -9.89M | -12.35M | -24.80M | -9.90M | 600.00K | -3.70M | 0.00 | 0.00 | 800.00K | 100.00K | -4.90M | -800.00K | -500.00K | -300.00K | -900.00K | -1.00M |
| Income Before Tax Ratio | -69.36% | -59.37% | 0.04% | -210.29% | 507.03% | 0.00% | 4.30% | -21.96% | -21.40% | -163.60% | -54.20% | -286.44% | -484.69% | -143.35% | -28.78% | 1.96% | -31.90% | 0.00% | 0.00% | 7.84% | 0.97% | -68.06% | -7.62% | -5.26% | -3.23% | -21.43% | -55.56% |
| Income Tax Expense | 0.00 | 132.51K | 694.46K | 1.03M | -1.99M | -91.98K | 40.00K | 238.00K | -1.07M | 1.16M | 0.00 | 1.63M | 1.71M | 300.00K | 9.30M | -200.00K | 2.80M | 1.30M | 1.60M | 100.00K | 1.10M | 800.00K | 100.00K | -1.40M | -1.50M | -900.00K | -500.00K |
| Net Income | -20.29M | -11.57M | -693.24K | -3.51M | 2.36M | -1.04M | 2.62M | -4.22M | 102.00K | -6.86M | -13.69M | -9.89M | -14.20M | -25.10M | -10.20M | 800.00K | -3.60M | -2.10M | -4.00M | 700.00K | 100.00K | -5.40M | -900.00K | -900.00K | -400.00K | -800.00K | -1.00M |
| Net Income Ratio | -68.24% | -60.06% | -20.35% | -297.76% | 3,270.20% | 0.00% | 3.73% | -21.66% | 0.75% | -163.60% | -54.20% | -286.44% | -557.44% | -145.09% | -29.65% | 2.61% | -31.03% | -14.58% | -36.04% | 6.86% | 0.97% | -75.00% | -8.57% | -9.47% | -4.30% | -19.05% | -55.56% |
| EPS | -0.24 | -0.16 | -0.01 | -0.06 | 0.05 | -0.02 | 0.63 | -1.28 | 0.06 | -14.23 | -224.38 | -300.80 | -545.05 | -6.48K | -3.60K | 280.00 | -1.26K | -735.04 | -1.40K | 245.01 | 35.00 | -1.89K | -315.02 | -315.02 | -140.01 | -280.01 | -350.02 |
| EPS Diluted | -0.24 | -0.16 | -0.01 | -0.06 | 0.02 | -0.02 | 0.35 | -1.28 | 0.06 | -14.23 | -224.38 | -300.80 | -545.05 | -6.48K | -3.60K | 240.00 | -1.26K | -735.04 | -1.40K | 245.01 | 35.00 | -1.89K | -315.02 | -315.02 | -140.01 | -280.01 | -350.02 |
| Weighted Avg Shares Out | 83.76M | 72.22M | 70.32M | 56.80M | 47.43M | 47.28M | 4.11M | 3.29M | 1.66M | 481.58K | 61.01K | 32.87K | 26.05K | 3.87K | 2.83K | 2.50K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K |
| Weighted Avg Shares Out (Dil) | 83.76M | 72.22M | 128.95M | 56.80M | 102.58M | 47.28M | 19.35M | 3.29M | 1.66M | 481.58K | 61.01K | 32.87K | 26.05K | 3.87K | 2.83K | 2.92K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K | 2.86K |
Dalrada's Genefic Wellness Group Launches New Infusion Clinics to Deliver Successful Alternative Therapies
Dalrada's Genefic Launches Achieve Weight-Loss and Wellness to Target Emerging Weight Loss Market
Dalrada's Energy Services' Subsidiary Licenses its Intellectual Property and Technical Knowledge to Pando Infrastructure
Dalrada Pharmaceutical Subsidiary, Watson Rx Solutions, Earns Prestigious NABP Specialty Pharmacy and Digital Pharmacy Accreditation
Dalrada Corporation Announces the Opening of its Heat Pump Showroom in Las Vegas
Dalrada Continues Corporate Restructuring Efforts with Streamlined Operations and Leadership to Improve Subsidiary Interaction and Reduce SG&A
Dalrada Corporation Announces Further European Expansion, Creates Dalrada Technology Spain, S.L.
Dalrada says DES clean energy subsidiary inks partnership deal with Banyan Infrastructure to boost ESG banking transparency
Dalrada Financial appoints professor Elizabeth Winzeler to its healthcare advisory board
Dalrada brings on Brian McGoff as its new president and COO
Source: https://incomestatements.info
Category: Stock Reports